One retinoblastoma study showed that the targeted depletion of UHRF1 significantly enhances the sensitivity of retinoblastoma cells to a panel of chemotherapeutic agents including etoposide, camptothecin, and carboplatin [66]. This evidence concerns the gene UHRF1 and retinoblastoma.